NASDAQ:INSY - Insys Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.86 -0.21 (-2.97 %)
(As of 05/27/2018 03:49 AM ET)
Previous Close$6.86
Today's Range$6.84 - $7.18
52-Week Range$4.10 - $15.02
Volume488,664 shs
Average Volume591,814 shs
Market Capitalization$521.83 million
P/E Ratio-14.00
Dividend YieldN/A
Beta1.02

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Receive INSY News and Ratings via Email

Sign-up to receive the latest news and ratings for INSY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSY
CUSIPN/A
Phone480-500-3127

Debt

Debt-to-Equity RatioN/A
Current Ratio0.84
Quick Ratio0.76

Price-To-Earnings

Trailing P/E Ratio-14.00
Forward P/E Ratio-7.54
P/E GrowthN/A

Sales & Book Value

Annual Sales$140.69 million
Price / Sales3.60
Cash FlowN/A
Price / CashN/A
Book Value$0.64 per share
Price / Book10.72

Profitability

EPS (Most Recent Fiscal Year)($0.49)
Net Income$-228,010,000.00
Net Margins-188.01%
Return on Equity-43.27%
Return on Assets-17.51%

Miscellaneous

Employees343
Outstanding Shares73,810,000

Insys Therapeutics (NASDAQ:INSY) Frequently Asked Questions

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Shares of Insys Therapeutics split on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were payable to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics (NASDAQ:INSY) posted its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.01. The specialty pharmaceutical company earned $23.90 million during the quarter, compared to analysts' expectations of $25.82 million. Insys Therapeutics had a negative net margin of 188.01% and a negative return on equity of 43.27%. Insys Therapeutics's quarterly revenue was down 33.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.09) earnings per share. View Insys Therapeutics' Earnings History.

When is Insys Therapeutics' next earnings date?

Insys Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Insys Therapeutics.

What price target have analysts set for INSY?

5 equities research analysts have issued 12 month target prices for Insys Therapeutics' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Insys Therapeutics' share price to reach $9.6667 in the next year. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:
  • Mr. Steven J. Meyer, Exec. Chairman (Age 61)
  • Mr. Franc Del Fosse, Gen. Counsel and Corp. Sec. (Age 46)
  • Mr. Saeed Motahari, Pres, CEO & Director (Age 52)
  • Mr. Andrew G. Long, Chief Financial Officer
  • Mr. B. Sanga Emmanuel, VP & Chief Compliance Officer

Has Insys Therapeutics been receiving favorable news coverage?

Headlines about INSY stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insys Therapeutics earned a news impact score of 0.13 on Accern's scale. They also gave press coverage about the specialty pharmaceutical company an impact score of 46.77 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Insys Therapeutics' major shareholders?

Insys Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.31%), ETF Managers Group LLC (0.88%), DekaBank Deutsche Girozentrale (0.04%) and JPMorgan Chase & Co. (0.03%). Company insiders that own Insys Therapeutics stock include Brian Tambi, Daniel Brennan, John N Kapoor Trust Dated Sept, Patrick Fourteau, Rohit Vishnoi, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Which major investors are selling Insys Therapeutics stock?

INSY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Insys Therapeutics.

Which major investors are buying Insys Therapeutics stock?

INSY stock was bought by a variety of institutional investors in the last quarter, including ETF Managers Group LLC and JPMorgan Chase & Co.. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy shares of Insys Therapeutics?

Shares of INSY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of INSY stock can currently be purchased for approximately $6.86.

How big of a company is Insys Therapeutics?

Insys Therapeutics has a market capitalization of $521.83 million and generates $140.69 million in revenue each year. The specialty pharmaceutical company earns $-228,010,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. Insys Therapeutics employs 343 workers across the globe.

How can I contact Insys Therapeutics?

Insys Therapeutics' mailing address is 1333 S. Spectrum Blvd Suite 100, Chandler AZ, 85286. The specialty pharmaceutical company can be reached via phone at 480-500-3127 or via email at [email protected]


MarketBeat Community Rating for Insys Therapeutics (INSY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  233 (Vote Underperform)
Total Votes:  554
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe INSY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insys Therapeutics (NASDAQ:INSY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Insys Therapeutics in the last 12 months. Their average twelve-month price target is $9.6667, suggesting that the stock has a possible upside of 40.91%. The high price target for INSY is $11.00 and the low price target for INSY is $8.00. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.202.202.502.50
Ratings Breakdown: 1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.6667$9.6667$9.6667$9.6667
Price Target Upside: 40.91% upside29.23% upside87.34% upside87.34% upside

Insys Therapeutics (NASDAQ:INSY) Consensus Price Target History

Price Target History for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ:INSY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2018OppenheimerReiterated RatingHoldLowView Rating Details
3/9/2018Piper Jaffray CompaniesDowngradeNeutral ➝ UnderweightHighView Rating Details
3/2/2018CannReiterated RatingAverageHighView Rating Details
11/3/2017Jefferies GroupLower Price TargetBuy$14.00 ➝ $11.00N/AView Rating Details
10/27/2017Royal Bank of CanadaSet Price TargetBuy$8.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Insys Therapeutics (NASDAQ:INSY) Earnings History and Estimates Chart

Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ:INSY) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.91 EPS
Next Year EPS Consensus Estimate: $-0.61 EPS

Insys Therapeutics (NASDAQ INSY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2018($0.18)N/AView Earnings Details
5/8/2018Q1 2018($0.18)($0.19)$25.82 million$23.90 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.14)($0.61)$34.00 million$31.49 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.23)($0.25)$34.98 million$30.67 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.09)$0.03$36.90 million$42.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016($0.0020)$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
5/13/2014Q1 2014$0.14$0.18$46.00 million$41.64 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
8/26/2010Q2 2010($0.59)ViewN/AView Earnings Details
6/11/2010Q1 2010($1.02)ViewN/AView Earnings Details
3/18/2010Q4 2009($0.33)ViewN/AView Earnings Details
10/26/2009Q3 2009($1.26)ViewN/AView Earnings Details
7/27/2009Q2 2009($1.42)ViewN/AView Earnings Details
4/28/2009Q1 2009($1.61)ViewN/AView Earnings Details
3/4/2009Q4 2008($1.59)ViewN/AView Earnings Details
11/12/2008Q3 2008($1.71)ViewN/AView Earnings Details
8/14/2008Q2 2008($1.48)ViewN/AView Earnings Details
5/12/2008Q1 2008($1.08)ViewN/AView Earnings Details
3/27/2008Q4 2007($0.75)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Insys Therapeutics (NASDAQ:INSY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insys Therapeutics (NASDAQ INSY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 17.79%
Insider Trading History for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics (NASDAQ INSY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/10/2018Brian TambiDirectorSell166,504$6.41$1,067,290.644,000View SEC Filing  
8/11/2017John N Kapoor Trust Dated SeptMajor ShareholderBuy17,500$8.93$156,275.0031,982View SEC Filing  
8/10/2017Saeed MotahariCEOBuy5,500$8.92$49,060.0015,400View SEC Filing  
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.009,900View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.004,000View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.0052,083View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.004,500View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.0044,083View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.0017,000View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.0031,982View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.0049,682View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.961View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.0018,000View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.0031,982View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.0064,682View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.0031,982View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.0031,982View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.0079,682View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.002,000View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.006,100View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00105,000View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.243,125View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.565,375View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.003,125View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.003,125View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.003,125View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.0078,557View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.0065,000View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insys Therapeutics (NASDAQ INSY) News Headlines

Source:
DateHeadline
NYSE trader: Cannabis stocks are migrating from Canada to the US—a trend here to stayNYSE trader: Cannabis stocks are migrating from Canada to the US—a trend here to stay
finance.yahoo.com - May 26 at 3:18 PM
INSYS Gets Negative FDA Recommendation for Pain CandidateINSYS Gets Negative FDA Recommendation for Pain Candidate
finance.yahoo.com - May 23 at 3:19 PM
Insys Therapeutics (INSY) Confirms FDA Panel on Buprenorphine Voted Not to Recommend ApprovalInsys Therapeutics (INSY) Confirms FDA Panel on Buprenorphine Voted Not to Recommend Approval
www.streetinsider.com - May 23 at 8:10 AM
FDA advisory committees reject Insys buprenorphine sublingual sprayFDA advisory committees reject Insys' buprenorphine sublingual spray
seekingalpha.com - May 22 at 3:21 PM
INSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual SprayINSYS Therapeutics Confirms Outcome of FDA Advisory Committee Meeting on Buprenorphine Sublingual Spray
finance.yahoo.com - May 22 at 3:21 PM
$27.32 Million in Sales Expected for Insys Therapeutics (INSY) This Quarter$27.32 Million in Sales Expected for Insys Therapeutics (INSY) This Quarter
www.americanbankingnews.com - May 20 at 2:32 AM
-$0.15 Earnings Per Share Expected for Insys Therapeutics (INSY) This Quarter-$0.15 Earnings Per Share Expected for Insys Therapeutics (INSY) This Quarter
www.americanbankingnews.com - May 18 at 5:17 PM
INSYS down 5% premarket on Ad Com doc releaseINSYS down 5% premarket on Ad Com doc release
seekingalpha.com - May 18 at 3:20 PM
A Buvaya Failure Could Sting InsysA Buvaya Failure Could Sting Insys
seekingalpha.com - May 18 at 3:20 PM
This Pot Stock's First-Quarter Report Is Creating All the Wrong BuzzThis Pot Stock's First-Quarter Report Is Creating All the Wrong Buzz
finance.yahoo.com - May 16 at 3:24 PM
Insys Therapeutics (INSY) Comments on Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation EffortsInsys Therapeutics (INSY) Comments on Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts
www.streetinsider.com - May 16 at 6:54 AM
[$$] U.S. Joins Whistleblower Suits Against Opioid Maker[$$] U.S. Joins Whistleblower Suits Against Opioid Maker
finance.yahoo.com - May 16 at 6:54 AM
BRIEF-Insys Therapeutics Responds To Unsealing Of Previously Filed Qui Tam ComplaintsBRIEF-Insys Therapeutics Responds To Unsealing Of Previously Filed Qui Tam Complaints
www.reuters.com - May 15 at 3:19 PM
INSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation EffortsINSYS Therapeutics Responds to Unsealing of Previously Filed Qui Tam Complaints and Recaps Transformation Efforts
finance.yahoo.com - May 15 at 3:19 PM
Insys sees no change in estimated litigation costsInsys sees no change in estimated litigation costs
finance.yahoo.com - May 15 at 3:19 PM
U.S. joins whistleblower case against Insys over kickbacksU.S. joins whistleblower case against Insys over kickbacks
finance.yahoo.com - May 15 at 7:37 AM
Whistleblower case that convinced government to investigate Insys Therapeutics is publicly revealed for first timeWhistleblower case that convinced government to investigate Insys Therapeutics is publicly revealed for first time
www.prnewswire.com - May 15 at 12:48 AM
Insys Therapeutics (INSY) Director Brian Tambi Sells 166,504 SharesInsys Therapeutics (INSY) Director Brian Tambi Sells 166,504 Shares
www.americanbankingnews.com - May 14 at 7:26 PM
More evidence companies pay some doctors to prescribe opioidsMore evidence companies pay some doctors to prescribe opioids
www.nbcnews.com - May 14 at 3:20 PM
Edited Transcript of INSY earnings conference call or presentation 8-May-18 9:00pm GMTEdited Transcript of INSY earnings conference call or presentation 8-May-18 9:00pm GMT
finance.yahoo.com - May 10 at 3:19 PM
Insys Therapeutics (INSY) Lifted to "Hold" at Zacks Investment ResearchInsys Therapeutics (INSY) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 1:02 PM
Insys Therapeutics (INSY) Earns Hold Rating from OppenheimerInsys Therapeutics (INSY) Earns Hold Rating from Oppenheimer
www.americanbankingnews.com - May 9 at 6:50 PM
I Was Flat-Out Wrong About This Marijuana StockI Was Flat-Out Wrong About This Marijuana Stock
finance.yahoo.com - May 9 at 3:21 PM
BRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle EastBRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East
www.reuters.com - May 9 at 5:55 AM
Insys Therapeutics (INSY) CEO Saeed Motahari on Q1 2018 Results - Earnings Call TranscriptInsys Therapeutics' (INSY) CEO Saeed Motahari on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:55 AM
Insys Therapeutics, Inc. 2018 Q1 - Results - Earnings Call SlidesInsys Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 9 at 5:55 AM
INSYS Therapeutics Reports First Quarter 2018 ResultsINSYS Therapeutics Reports First Quarter 2018 Results
finance.yahoo.com - May 9 at 5:55 AM
Insys Therapeutics: 1Q Earnings SnapshotInsys Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 5:55 AM
INSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle EastINSYS Therapeutics Announces Exclusive License Partnership with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East
finance.yahoo.com - May 9 at 5:55 AM
Insys Therapeutics (INSY) Releases  Earnings Results, Misses Estimates By $0.03 EPSInsys Therapeutics (INSY) Releases Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 8 at 10:44 PM
Insys Therapeutics (INSY) Receives Average Recommendation of "Hold" from AnalystsInsys Therapeutics (INSY) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 6 at 1:08 AM
The pain hustlers: One company paid millions to doctors to push their painkillersThe pain hustlers: One company paid millions to doctors to push their painkillers
www.cnbc.com - May 4 at 12:47 PM
Insys Therapeutics (INSY) Lowered to "Strong Sell" at ValuEngineInsys Therapeutics (INSY) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - May 3 at 10:34 PM
Zacks: Brokerages Anticipate Insys Therapeutics (INSY) Will Post Quarterly Sales of $24.72 MillionZacks: Brokerages Anticipate Insys Therapeutics (INSY) Will Post Quarterly Sales of $24.72 Million
www.americanbankingnews.com - May 3 at 4:38 AM
The Opioid That Made a Fortune for Its Maker — and for Its PrescribersThe Opioid That Made a Fortune for Its Maker — and for Its Prescribers
www.nytimes.com - May 2 at 5:34 AM
Zacks: Analysts Expect Insys Therapeutics (INSY) to Post -$0.19 EPSZacks: Analysts Expect Insys Therapeutics (INSY) to Post -$0.19 EPS
www.americanbankingnews.com - May 1 at 5:22 AM
Insys Therapeutics (INSY) Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi SyndromeInsys Therapeutics (INSY) Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome
www.streetinsider.com - April 28 at 5:20 AM
INSYS launches mid-stage study of CBD in rare obesity disorderINSYS launches mid-stage study of CBD in rare obesity disorder
seekingalpha.com - April 27 at 3:14 PM
INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi SyndromeINSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome
finance.yahoo.com - April 27 at 3:14 PM
INSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical TrialINSYS Therapeutics and University of California (UC) San Diego Center for Medicinal Cannabis Research to Collaborate on Clinical Trial
finance.yahoo.com - April 26 at 3:19 PM
INSYS Therapeutics to Report First Quarter 2018 Results on May 8INSYS Therapeutics to Report First Quarter 2018 Results on May 8
finance.yahoo.com - April 25 at 6:24 AM
Ex-Insys employee in U.S. opioid case sentenced to home confinementEx-Insys employee in U.S. opioid case sentenced to home confinement
finance.yahoo.com - April 24 at 5:39 AM
Insys Therapeutics (INSY) Upgraded by Zacks Investment Research to "Strong-Buy"Insys Therapeutics (INSY) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - April 18 at 10:16 PM
BRIEF-Insys Therapeutics To Advance Clinical Research Of Dronabinol Inhalation Using Novel Breath-Actuated DeviceBRIEF-Insys Therapeutics To Advance Clinical Research Of Dronabinol Inhalation Using Novel Breath-Actuated Device
www.reuters.com - April 18 at 3:21 PM
INSYS to advance research on dronabinol inhalation via novel device; shares up 6%INSYS to advance research on dronabinol inhalation via novel device; shares up 6%
seekingalpha.com - April 18 at 3:21 PM
INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated DeviceINSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device
finance.yahoo.com - April 18 at 3:21 PM
Drug Made From Cannabis Plant Gets Backing From FDA StaffDrug Made From Cannabis Plant Gets Backing From FDA Staff
finance.yahoo.com - April 17 at 10:31 AM
Insys Therapeutics (INSY) Lowered to Hold at BidaskClubInsys Therapeutics (INSY) Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 16 at 9:48 AM
Insys Therapeutics (INSY) Expected to Post Quarterly Sales of $26.09 MillionInsys Therapeutics (INSY) Expected to Post Quarterly Sales of $26.09 Million
www.americanbankingnews.com - April 16 at 4:19 AM
Insys Therapeutics (INSY) Given a $10.00 Price Target by Piper Jaffray AnalystsInsys Therapeutics (INSY) Given a $10.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 15 at 11:42 PM

SEC Filings

Insys Therapeutics (NASDAQ:INSY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insys Therapeutics (NASDAQ:INSY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insys Therapeutics (NASDAQ INSY) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.